Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD
Sponsor: Aer Therapeutics
Summary
AER-01-002 is a Phase 2a study being conducted to determine if inhaled fexlamose is an effective and safe treatment for adults with moderate to severe COPD. Study will compare active drug to placebo.
Official title: A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER-01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-12
Completion Date
2026-01
Last Updated
2024-12-13
Healthy Volunteers
No
Conditions
Interventions
Flexlamose
Fexlamose solution via nebulizer for 28 days
Placebo
Placebo solution via nebulizer for 28 days